as I expected, the management and market match was officially...

as I expected, the management and market match was officially opened to obtain the requirements for the assignment of the options expiring next 29 May. management needs a price per share of more than 1.64 / 1.84, a level that the market instead tries to disregard to invalidate the option right. the two news of today were in the drawer for some time and the management decided to gamble on them trying to get a strong and significant signal, in fact in the first part of the session it was reached in a maximum price of 1.55; then the market that counts took the situation in hand and gradually reduced and controlled the price per share; now we have the company that however has recorded an important technical signal from the point of view of the breakdown of the negative trend and a price per share of support just below 1.20.differently, the market has shown that it has full control of the stock there being other institutional entities now motivated to significant purchases. the final challenge will be next week or in any case by the end of the month, when the management could and should play the decisive card that will make the difference, namely the sale of the Trofinetide rights which would mean a large amount of money that would allow refinancing the options without affecting the treasury of over 20 million already destined to 2591.regarding the content of the news, what has been said in the past follows; the 2591 project provides first of all a series of modest spending trials and with a good guarantee of success, which together open up the spectrum of the autistic spectrum; secondly, the advancement to the neuro degenerative studies that count and make an enormous difference on the market; fully satisfied that a high profile partnership is needed for this last step.we look forward to renewed confidence in the change of pace on the market.